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Background:  Brugada  syndrome  is a  cardiac  disorder  associated  with  a high risk  of  sudden  cardiac  death,
especially  in  young  subjects.  The  incidence  and  prevalence  are likely  underestimated.  The  diagnosis  is
based  on  a characteristic  electrocardiography  (ECG)  pattern.  The  most  commonly  performed  conﬁrma-
tory  test  in  cases  of equivocal  ECG  is  the  intravenous  ajmaline  challenge.  Although  relatively  safe,  it
carries  the  risk  of ventricular  arrhythmias  that could  potentially  degenerate  into  a refractory  electrical
storm.
Case  report:  A  27-year-old  man developed  sustained  ventricular  ﬁbrillation  after  ajmaline  challenge.  He
was  rescued  on  extracorporeal  life  support  after  108  min  of cardiopulmonary  resuscitation.  Extracor-xtracorporeal  life support
ild  therapeutic hypothermia
poreal  life  support  allowed  recovery  of spontaneous  circulation  and  resulted  in a positive  neurological
outcome.
<Learning  objective:  This case  is an  example  of  how  extracorporeal  life  support  was  instituted  after
prolonged  and unsuccessful  cardiopulmonary  resuscitation  resulting  in a positive  central  neurological
outcome.>
©  2014  Japanese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroduction
Brugada syndrome (BS) is a cardiac disorder, with electro-
ardiographic features of pseudo-right bundle-branch block and
ersistent ST-segment elevation in leads V1–V3 with high risk of
udden cardiac death [1,2]. This disorder is genetically transmitted
nd mostly due to mutations in the gene encoding for the alpha-
ubunit of the cardiac sodium channel, SCN5A.
Intravenous ajmaline challenge (Class IA antiarrhythmic), using
 protocol with fractionated drug administration is a widely
ccepted safe method to conﬁrm the diagnosis of BS when the res-
ing electrocardiogram (ECG) is not diagnostic. Despite the risk of
nduced ventricular dysrhythmias, ajmaline is considered the drug
f choice given its short duration and higher sensitivity compared
o other Na+ channel blockers [3]. Ajmaline-induced ventricular
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arcelona,  Spain. Tel.: +34 93 227 55 58; fax: +34 93 227 54 54.
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878-5409/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights rearrhythmias are often refractory to electrical therapy thus requiring
prolonged circulatory support.
We report a case of a sustained ventricular ﬁbrillation (VF) after
ajmaline challenge test in whom innovative strategies for treating
cardiac arrest were used.
Case  report
A  27-year-old asymptomatic male presented to our tertiary care
center for BS testing due to his positive family history (brother diag-
nosed with BS). His past medical history included whooping cough
at 3 months and a spontaneous pneumothorax at 17 years. An ini-
tial ﬂecainide test (2 mg/kg for 10 min) was  not fully diagnostic,
but suggestive of BS due to ST elevation in V2 of 2 mm (Fig. 1). An
ajmaline test was then performed.
A ﬁrst ajmaline bolus of 0.7 mg/kg over 5 min  was given intra-
venously but failed to unmask an ECG BS pattern. A second bolus of
1 mg/kg over 5 min  was then administered. During the infusion, the
patient suddenly developed a polymorphic ventricular tachycar-
dia that rapidly degenerated into VF (Fig. 2). External deﬁbrillation
served.
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Fig. 1. Flecainide test (2 mg/kg for 10 min). Electrocardiogram: (a) baseline: sinus rhythm at 60 bpm. (b) At the end: sinus rhythm, ST elevation in V2 of 2 mm (very suggestive
of  Brugada syndrome).
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Fig. 2. Ajmaline test. In the ﬁrst 4 min  (a) electrocardiographic changes were recorded. (b) At the 5th minute the patient suddenly developed a polymorphic ventricular
tachycardia that rapidly degenerated into ventricular ﬁbrillation.
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as unsuccessful and cardiopulmonary resuscitation (CPR) was
tarted according to the European Resuscitation Council guide-
ines. During CPR, adrenaline was given at a rate of 1 mg  every
 min, followed by a continuous intravenous infusion of isopro-
erenol (10 g/min). Hypertonic sodium bicarbonate was given at
 meq./kg as a rapid intravenous bolus followed by an infusion
f 250 meq./h of 8.4% sodium bicarbonate. Electrolyte replace-
ent included: 1 g of calcium gluconate and 1.5 g of magnesium
ulphate. The airway was secured with endotracheal intubation
 min  after CPR was started. A refractory electrical storm per-
isted after 20 min  of CPR and 10 shocks; a 20% lipid emulsion
nfusion was started at this point at a rate of 0.25 mL  kg−1 min−1
fter 1 mL/kg bolus over 1 min. Quinidine was considered but
as not available on the ﬂoor at this moment and a cardiac sur-
eon was consulted to place the patient on mechanical circulatory
upport [4,5].
For  more effective chest compressions and not to discontinue
PR during surgical cannulation, an external cardiac compressor
Lund University Cardiac Arrest System, LUCASTM, Lund, Sweden)
as used. Extracorporeal life support (ECLS) was ﬁnally instituted
fter 107 min  of CPR and 53 unsuccessful deﬁbrillation attempts.
n extracorporeal membrane oxygenator (ECMO) circuit was  used
roviding a ﬂow between 3 and 4.5 l/min at 2415–3275 rpm, sweep
f 7–3.5 l/min, and a variable inspired fraction of oxygen. Mild
herapeutic hypothermia (MTH) was initiated for cerebral pro-
ection with a target temperature of 33 ◦C for 24 h followed by
ctive rewarming at 0.25 ◦C/h to normothermia using the ECLS
evice [6]. The patient ﬁnally recovered a stable sinus rhythm,
18 min  after ECLS initiation and pulmonary artery catheter was
laced for hemodynamic monitoring at this point. Normal ventricu-
ar function was shown by transthoracic echocardiography at 24 h
ost-arrest.
ECLS was successfully weaned 43 h post-arrest and the patient
ecannulated. The patient was ﬁnally extubated 4 days later.
eurological examination at the time post-extubation revealed
ltered T5 sensation level, paresthesia, and weakness in both
ower limbs, slight cognitive dysfunction characterized by slow
deation and minor difﬁculty in calculation. A nuclear magnetic
esonance showed an intramedullary alteration at the level of
edullar conus, suggesting an acute–subacute ischemia (Fig. 3).
n implantable cardioverter-deﬁbrillator was placed and the
atient was then discharged to a speciﬁc neuro-rehabilitation
enter  21 days after the arrest. At 1-year follow-up, the patient
ig. 3. Nuclear magnetic resonance imaging. Intramedullary alteration at the level
f medullar conus, suggesting an acute–subacute ischemia.ogy Cases 10 (2014) 34–38 37
presented with improved cognitive function and unchanged
paraplegia.
Discussion
BS is genetically transmitted and mostly due to mutations in the
gene encoding for the alpha-subunit of the cardiac sodium chan-
nel, SCN5A. Mutations in SCN5A gene lead to a decreased sodium
current by encoding a dysfunctional alpha-subunit of the voltage-
gated cardiac sodium channel, resulting in a modiﬁcation of the
ionic imbalance and a consequent change in the morphology of
the action potential during phase 1. Class I antiarrhythmics are
commonly used sodium channel blockers. Intravenous ajmaline
challenge has been described as a safe test to unmask the ECG
pattern of BS. Nevertheless, oral ajmaline poisoning may  be lethal
and 0.15% of patients undergoing intravenous ajmaline challenge
develop sustained VF commonly terminated by a single exter-
nal deﬁbrillator shock [3]. Quinidine and isoproterenol have been
reported to be a useful pharmacological treatment during refrac-
tory malignant ventricular dysrhythmias in BS, by rebalancing the
ionic currents affected by this condition. Hypertonic sodium bicar-
bonate, electrolyte replacement, and a 20% lipid emulsion are key
interventions in the early management of toxicity by these agents,
but often not enough to prevent a refractory cardiac arrest (CA)
unresponsive to conventional CPR.
In these circumstances, prolonged CPR may  be necessary. Stud-
ies show that high-quality chest compressions are difﬁcult to
maintain for long periods, even when performed by trained hos-
pital staff. Despite the setting, the environment, the response time,
the equipment, and experienced hospital staff, resuscitation skills
deteriorate over time. Mechanical devices are available in some
countries and widely used by out-of-hospital cardiac arrest (OHCA)
teams, but rarely used for in-hospital cardiac arrests (IHCAs). These
help to maintain good quality chest compressions during prolonged
periods, allow transportation, and interventional procedures such
as percutaneous coronary intervention without interrupting com-
pressions. However, a comparison of manual versus mechanical
chest compressions did not show any outcome difference in OHCA
[7].
IHCA has a reported initial survival rate of 38.6% with a survival
at discharge of about 15.9% [8], with neurological prognostication,
after recovery of spontaneous circulation, the main problem. The
use of combined therapeutic techniques in IHCA and OHCA such
as ECLS, MTH, and mitochondrial medicine with the addition of
regionalization (specialized centers with expert care in CA) are
helping to change the outcomes.
ECLS  has been suggested as a therapeutic option in refractory CA
since 1976. However, its use has remained limited to hypothermic
CA and the perioperative period of cardiothoracic surgery due to
the initial deceptive results. Recent miniaturized ECLS systems have
permitted a wider use. Encouraging results have been published. In
these studies, most cases were IHCA from toxic or cardiac causes,
down time was close to zero, and survival with good neurological
outcome up to 20–30% [9,10]. The aim of ECLS is to provide tempo-
rary perfusion to vital organs until injured myocardium recovers.
Indications for ECLS rescue in a CA have not been clearly deﬁned,
but cardiotoxic drugs intoxication and severe accidental hypother-
mia are two  widely accepted due to their reversibility. ECLS has
been more often proposed as an ultimate rescue in prolonged CA
and failing conventional CPR [11].
After recovery of spontaneous circulation, one of the main
concerns is neurological outcome. In the past decade, mild
hypothermia treatment has shown some degree of brain protection
in patients post-CA, especially when due to shockable rhythms. Two
positive large prospective randomized trials conducted in 2002 led
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[14]  Nagao K, Hayashi N, Kanmatsuse K, Arima K, Ohtsuki J, Kikushima K,
Watanabe I. Cardiopulmonary cerebral resuscitation using emergency car-
diopulmonary bypass, coronary reperfusion therapy and mild hypothermia in8 J. Moreno et al. / Journal of C
o the inclusion of MTH  in the ofﬁcial guidelines as a therapeutic
ool in the unconscious adult patients, with return to spontaneous
irculation after OHCA due to shockable rhythms and, since 2010,
t is also recommended after IHCA and CA due to non-shockable
hythms [12,13]. Some studies have shown that ECLS could provide
oth systemic cooling and hemodynamic support in cardiac arrest
atients, but future research should evaluate its usefulness and
afety [14].
In  summary, MTH  can be used safely in Brugada syndrome,
eversing the Brugada phenotype by the prevention of fever and
t the same time giving cerebral protection after cardiac arrest. In
ddition, the use of ECLS to provide cardiovascular support during
efractory electrical storm due to intrinsic cardiac disease such as
rugada or drug overdose has also been successfully used in those
ases.
onclusions
CA is a relatively common and lethal situation, with an estimated
ncidence in Europe of 375,000 a year. This implies that all emer-
ency physicians will face many cardiac arrests in their careers. As
rofessionals dedicated to emergencies, we need to be updated and
now that, currently, the ﬁeld of resuscitation is progressing con-
inuously trying to ﬁnd new techniques and resources to increase
urvival and improve neurological outcome in these patients.
The  novelty of this case is the therapeutic use of ECLS and
ypothermia as a bridge for a Class I antiarrhythmic drug toxic-
ty with sustained ventricular ﬁbrillation abnormally prolonged in
ime, with the help of LUCASTM device, trying to combine these
ew techniques and resources to ensure that a young man  gets
ack home alive and with his higher brain functions preserved.
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